Integra LifeSciences (NASDAQ:IART) Updates FY25 Earnings Guidance

Integra LifeSciences (NASDAQ:IART) issued an update on its FY25 earnings guidance on Tuesday morning. The company provided earnings per share guidance of $2.41 to $2.51 for the period, compared to the consensus earnings per share estimate of $2.53. The company issued revenue guidance of $1.650 billion to $1.715 billion, compared to the consensus revenue estimate of $1.71 billion. Integra LifeSciences also updated its FY 2025 guidance to 2.410-2.510 EPS.

Integra LifeSciences Price Performance

IART stock opened at $21.45 on Tuesday. The company has a market capitalization of $1.66 billion, a P/E ratio of -236.16, a price-to-earnings-growth ratio of 0.73 and a beta of 1.17. Integra LifeSciences has a 52-week low of $16.81 and a 52-week high of $44.91. The business has a 50-day simple moving average of $23.68 and a two-hundred day simple moving average of $21.81. The company has a debt-to-equity ratio of 0.79, a quick ratio of 0.73 and a current ratio of 1.20.

Integra LifeSciences (NASDAQ:IART) last released its quarterly earnings results on Tuesday, February 25th. The life sciences company reported $0.97 EPS for the quarter, beating analysts’ consensus estimates of $0.85 by $0.12. Integra LifeSciences had a positive return on equity of 12.35% and a negative net margin of 0.42%. The business had revenue of $442.65 million during the quarter, compared to analyst estimates of $445.15 million. During the same period in the prior year, the firm posted $0.89 EPS. Integra LifeSciences’s quarterly revenue was up 11.5% compared to the same quarter last year. Research analysts expect that Integra LifeSciences will post 2.45 EPS for the current fiscal year.

Analysts Set New Price Targets

IART has been the topic of a number of research analyst reports. Citigroup boosted their target price on Integra LifeSciences from $16.00 to $22.00 and gave the stock a “sell” rating in a research note on Tuesday, November 5th. Morgan Stanley initiated coverage on Integra LifeSciences in a research report on Monday, December 2nd. They issued an “underweight” rating and a $20.00 price objective on the stock. Three research analysts have rated the stock with a sell rating, five have issued a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $23.00.

Insider Activity at Integra LifeSciences

In related news, EVP Michael J. Mcbreen sold 1,700 shares of the stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $24.16, for a total value of $41,072.00. Following the completion of the transaction, the executive vice president now directly owns 56,182 shares of the company’s stock, valued at $1,357,357.12. This represents a 2.94 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 3.10% of the stock is owned by corporate insiders.

Integra LifeSciences Company Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.